COO Cooper Companies Inc.

CooperCompanies to Participate in the Oppenheimer Annual Healthcare Conference

CooperCompanies to Participate in the Oppenheimer Annual Healthcare Conference

SAN RAMON, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Daniel McBride, Esq, Executive Vice President, Chief Operating Officer & President of CooperVision, will represent the Company in a virtual session scheduled to begin at 1:10PM ET.

A live webcast of the Company’s session will be available on the Investor Relations section of CooperCompanies’ website at . An archived audio file will be available for replay on the same webpage later in the day.

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
18/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Cooper Companies Inc: 2 directors

Two Directors at Cooper Companies Inc bought 11,450 shares at between 68.390USD and 69.230USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

 PRESS RELEASE

CooperCompanies Announces Third Quarter 2025 Results

CooperCompanies Announces Third Quarter 2025 Results SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's ...

 PRESS RELEASE

CooperCompanies to Participate in the Wells Fargo Healthcare Conferenc...

CooperCompanies to Participate in the Wells Fargo Healthcare Conference SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global me...

 PRESS RELEASE

CooperCompanies Announces Release Date for Third Quarter 2025

CooperCompanies Announces Release Date for Third Quarter 2025 SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at . About...

 PRESS RELEASE

CooperCompanies Announces Second Quarter 2025 Results

CooperCompanies Announces Second Quarter 2025 Results SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second qu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch